Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, Wonchan | - |
dc.contributor.author | Jung, Keunok | - |
dc.contributor.author | Jeon, Youkyoung | - |
dc.contributor.author | Yun, Shik | - |
dc.contributor.author | Kim, Tae Woo | - |
dc.contributor.author | Choi, Inhak | - |
dc.date.accessioned | 2021-09-07T22:12:20Z | - |
dc.date.available | 2021-09-07T22:12:20Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2010-12-10 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/115123 | - |
dc.description.abstract | Tumor microenvironment has emerged as one of the major obstacles against the clinical efficacy of dendritic cell (DC) vaccines. Tumor-derived IL-6 may inhibit the differentiation of hematopoietic progenitor cells into DCs and suppress DC maturation, rendering DCs tolerogenic. We hypothesized that silencing the IL-6 receptor alpha chain (IL-6R alpha) would restore the functional competence of DC vaccines in mice with an IL-6-producing TC-1 tumor, and eventually give rise to protective immunity. We found that the IL-6R alpha knockdown-DC vaccine significantly enhanced the frequency of tumor-specific CD8(+) CTLs-producing effector molecules such as IFN-gamma, TNF-alpha, FasL, perforin, and granzyme B, and generated more CD8(+) memory T cells, leading to the substantially prolonged survival of TC-1 tumor-bearing mice. (C) 2010 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | INDOLEAMINE 2,3-DIOXYGENASE | - |
dc.subject | CD8-T-CELL MEMORY | - |
dc.subject | CD4-T-CELL HELP | - |
dc.subject | CANCER-PATIENTS | - |
dc.subject | PEPTIDE | - |
dc.subject | VACCINATION | - |
dc.subject | PROGRESSION | - |
dc.subject | EXPRESSION | - |
dc.subject | MELANOMA | - |
dc.subject | PATHWAY | - |
dc.title | Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Tae Woo | - |
dc.identifier.doi | 10.1016/j.vaccine.2010.10.027 | - |
dc.identifier.scopusid | 2-s2.0-78649688852 | - |
dc.identifier.wosid | 000286345000006 | - |
dc.identifier.bibliographicCitation | VACCINE, v.29, no.1, pp.34 - 44 | - |
dc.relation.isPartOf | VACCINE | - |
dc.citation.title | VACCINE | - |
dc.citation.volume | 29 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 34 | - |
dc.citation.endPage | 44 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | INDOLEAMINE 2,3-DIOXYGENASE | - |
dc.subject.keywordPlus | CD8-T-CELL MEMORY | - |
dc.subject.keywordPlus | CD4-T-CELL HELP | - |
dc.subject.keywordPlus | CANCER-PATIENTS | - |
dc.subject.keywordPlus | PEPTIDE | - |
dc.subject.keywordPlus | VACCINATION | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | MELANOMA | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordAuthor | Dendritic cell vaccine | - |
dc.subject.keywordAuthor | Knockdown | - |
dc.subject.keywordAuthor | IL-6 receptor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.